Related Experiment Video
Updated: Aug 5, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen
1Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792.
Background:
The growth of estrogen receptor (ER)-positive breast cancer cells is hormonally regulated, but the majority of breast cancers are ER negative and unresponsive to hormonal therapy.
Purpose And Methods:
To test whether hormonal control over replication can be re-established in ER-negative cells, we transfected ER-negative MDA-MB-231 (clone 10A) cells with sense and antisense constitutive ER expression vectors containing the gene for either wild-type or mutant ER linked to the gene for neomycin resistance aminoglycoside phosphotransferase (neo). A Northern blot analysis was done on total RNA from eight of the 10 transfectant clones produced to detect messenger RNA coding for ER and neo, and a Western blot analysis was done on protein extracted from the cells of one mutant and two wild-type ER sense transfectant clones to determine the molecular weight of the ER in transfectants. Levels of ER in transfectants were measured both by enzyme immunoassay and by ligand-binding methods. To ascertain whether the ER in wild-type and mutant sense transfectants was functional, we tested the effects of 17 beta-estradiol (E2) and/or an antiestrogen, ICI 164,384, on 1) ER-activated gene regulation (by transient transfection of these cells a second time with a reporter plasmid containing an estrogen response element linked to the chloramphenicol acetyl transferase [CAT] gene), 2) induction of progesterone receptor, 3) DNA replication, and 4) cell cycle kinetics.
Results:
Messenger RNA coding for ER and for neo was detectable in both sense and antisense transfectant clones. Sense transfectants (both mutant and wild-type) expressed ER protein with a molecular weight similar to that found in ER-positive control cells. By the ligand-binding method high levels of ER were detected in both wild-type and mutant transfectants, although by the enzyme immunoassay method lower levels were detected in mutant transfectants. ER from both wild-type and mutant sense transfectants appeared functional, since E2 stimulated the expression of reporter-linked CAT and of progesterone receptor in these transfectants. E2 inhibited DNA replication in wild-type sense transfectants at a concentration of 10(-10) M and mutant sense transfectants at a concentration of 10(-8) M, and ICI 164,384 blocked this effect.
Conclusion:
ER-negative breast cancer cells stably transfected with either a mutant or wild-type ER gene regain hormonal responsiveness; however, E2 inhibits rather than stimulates cell growth.
Implication:
Reactivation of quiescent ER may provide a novel therapeutic approach for controlling ER-negative breast cancers.
Insights
Estrogen receptor-negative breast cancer cells regained hormonal responsiveness after transfection with estrogen receptor (ER) genes. However, estradiol inhibited cell growth, suggesting a novel therapeutic strategy for ER-negative cancers.
Area of Science:
- Molecular Biology
- Cancer Research
- Endocrinology
Background:
- Estrogen receptor (ER)-positive breast cancer growth is hormone-dependent.
- ER-negative breast cancers are unresponsive to hormonal therapies.
- Developing therapeutic strategies for ER-negative breast cancer is crucial.
Purpose of the Study:
- To determine if hormonal control over replication can be re-established in ER-negative cells.
- To investigate the functionality of transfected wild-type and mutant ER in ER-negative cells.
- To explore potential therapeutic approaches for ER-negative breast cancer.
Main Methods:
- Transfection of ER-negative MDA-MB-231 cells with ER expression vectors.
- Northern and Western blot analyses to detect ER and neomycin resistance (neo) mRNA and protein.
- Enzyme immunoassay and ligand-binding assays to quantify ER levels.
- Functional assays including reporter gene activation, progesterone receptor induction, DNA replication, and cell cycle kinetics analysis.
Main Results:
- Transfected ER-negative cells expressed ER mRNA and protein.
- Transfected ER (both wild-type and mutant) was functional, responding to 17 beta-estradiol (E2) and antiestrogen ICI 164,384.
- E2 inhibited DNA replication in transfected cells, an effect blocked by ICI 164,384.
Conclusions:
- Stable transfection of ER-negative breast cancer cells with ER genes restores hormonal responsiveness.
- Estradiol inhibits, rather than stimulates, cell growth in these reactivated cells.
- Reactivating ER in ER-negative breast cancer presents a potential novel therapeutic avenue.
Related Concept Videos
Complementary DNA
Mitogens and the Cell Cycle

